Waters remain choppy for Vytorin as SEAS publication renews cancer fears
This article was originally published in Scrip
Executive Summary
Merck/Schering-Plough Pharmaceuticals' troubled combination hypolipaemic Vytorin (ezetimibe plus simvastatin) is once again in the spotlight following the presentation of the full SEAS data at the European Society of Cardiology meeting in Munich and their simultaneous publication online in the New England Journal of Medicine.